Everett Rand Sutherland - 02 Jan 2026 Form 4 Insider Report for Upstream Bio, Inc. (UPB)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
06 Jan 2026, 17:15:02 UTC
Prior SEC filing
30 Jun 2025
Next SEC filing
17 Mar 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Allison Ambrose, Attorney-in-Fact

Key filing fact

Everett Rand Sutherland filed Form 4 for Upstream Bio, Inc. (UPB) on 06 Jan 2026.

Key facts

  • This page summarizes Everett Rand Sutherland's Form 4 filing for Upstream Bio, Inc. (UPB).
  • 2 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 06 Jan 2026, 17:15.

Change

  • Previous filing in this sequence was filed on 30 Jun 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001852880 Primary reporting owner

Sutherland Everett Rand

Relationship
Chief Executive Officer, Director
Address
UPSTREAM BIO, INC., 890 WINTER STREET, SUITE 200, WALTHAM
Signature
/s/ Allison Ambrose, Attorney-in-Fact
Signature date
06 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

UPB transaction

Common Stock

Award

Transaction value
$0
Shares
+75,000
Change %
Price
$0.000000
Shares after
75,000
Date
02 Jan 2026
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

UPB transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
$0
Shares
+225,000
Change %
Price
$0.000000
Shares after
225,000
Date
02 Jan 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
225,000
Exercise price
$27.07
Footnotes
F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2024 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting. The RSUs shall vest in sixteen equal quarterly installments following January 1, 2026, subject to the Reporting Person's continued service on each such vesting date.

Footnote F2

The shares underlying this option shall vest in forty-eight equal monthly installments following January 1, 2026, subject to the Reporting Person's continued service on each such vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .